Advertisement
Skilled team provides advanced surgical interventions
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Liver resection continues to be a mainstay treatment for patients presenting with primary and secondary liver malignancies. In the case of hepatocellular carcinoma (HCC), liver resection is a curative alternative. However in HCC patients with cirrhosis and portal hypertension, liver transplantation is the standard of care.
Pretransplant locoregional therapy or liver resection are common approaches to keep patients within transplant eligibility. In line with this, organ allocation in HCC patients undergoing transplantation in the setting of severe organ scarcity continues to be challenging, as accurate predictors of posttransplant tumor recurrence are lacking.
At Cleveland Clinic’s Hepato-Biliary Cancer Center, we offer advanced surgical interventions via sophisticated surgical techniques to patients with complex tumors.
The patient is a 77-year-old male diagnosed with a large, central HCC abutting the portal vein bifurcation. After undergoing evaluation at a large, out-of-state tertiary facility, the patient received locoregional therapy but was denied surgery due to his age and advanced disease.
Seeking a surgical option and therefore a second opinion, the patient consulted the multidisciplinary Liver Tumor Clinic at Cleveland Clinic.
A large R0 central hepatectomy was successfully performed and the patient was discharged from the hospital on post-operative Day 7 without complications.
Total vascular control (supra-hepatic and infra-hepatic vena cava, and liver hilum) in preparation for parenchymal transection.
Advertisement
Cross sectional imaging via computed tomography demonstrating a large central liver mass (hepatocellular carcinoma).
Surgical resection bed (histopathology analysis confirmed negative tumor margins).
References
Advertisement
Advertisement
Researchers develop first-of-its-kind neoantigen atlas to better understand immunotherapy resistance
What’s coming up at ASH and beyond
Combining mind, body and lifestyle practices in alignment with conventional cancer treatment
Higher type 2 immunity observed in persistent CAR T cells
Pregnancy did not appear to increase the risk of recurrence in patients or complications in their children
Integrated program addresses growing need for comprehensive cancer care among adolescents, young adults and adults under 50 with early onset cancers
Studies find mTOR inhibitor may play key role in treating Hurthle cell carcinoma
Obstructing key protein allows for increased treatment uptake for taxane chemotherapy